BOSTON — SOPHiA GENETICS and Myriad Genetics have announced a collaboration to advance a new genomic testing technology designed to improve precision medicine approaches for prostate cancer patients.
The partnership will focus on developing and expanding access to the prostate genomic instability score (PrGIS), a biomarker designed to identify chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer.
The companies will work to advance the technology in clinical trials and develop potential companion diagnostic solutions to help identify patients who may benefit from targeted cancer treatments. The collaboration also supports precision oncology initiatives involving AstraZeneca.
Myriad Genetics developed PrGIS to assess HRD, an emerging biomarker that could help predict disease progression and treatment response in prostate cancer patients.
The company’s MyChoice CDx test, currently used as a companion diagnostic in ovarian cancer, will generate the PrGIS score as Myriad works to expand the technology into prostate cancer testing.
“This collaboration showcases Myriad’s biopharma capabilities to support development of precision oncology treatments,” said Lou Welebob, Senior Vice President, Companion Diagnostics at Myriad Genetics. “PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies.”
Under the agreement, SOPHiA GENETICS will integrate Myriad’s PrGIS technology into its Extended Homologous Recombination Solution, creating a decentralized companion diagnostic platform designed to make testing available through local laboratories worldwide.
SOPHiA GENETICS operates a cloud-based platform connecting more than 1,000 healthcare institutions across more than 75 countries. The companies said the collaboration could help expand access to advanced genomic testing beyond major medical markets.
“Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world,” said Jess Lambe, Vice President and Managing Director of BioPharma Business Development at SOPHiA GENETICS.
“By pairing Myriad’s world-class biomarker innovation with SOPHiA GENETICS’ global network, we are working toward a solution for this. Together, we’re building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most,” Lambe added.
Myriad Genetics also plans to present additional research on PrGIS at the European Society for Medical Oncology (ESMO) Congress 2026.
The research, co-authored with AstraZeneca, is expected to provide further information about the biomarker’s potential clinical applications and support its validation for prostate cancer testing.
The companies said the initiative is intended to strengthen precision oncology by helping physicians identify patients who may be more likely to benefit from specific cancer therapies.
